Professional Documents
Culture Documents
Potential Impact of Biofield Treatment On Atomic and Physical Characteristics of Magnesium
Potential Impact of Biofield Treatment On Atomic and Physical Characteristics of Magnesium
Mg
Magnesium
Trivedi Global Inc., 10624 S Eastern Avenue Suite A-969, Henderson, NV 89052, USA
Trivedi Science Research Laboratory Pvt. Ltd., Hall-A, Chinar Mega Mall, Chinar Fortune City, Hoshangabad Rd.,
Bhopal- 462026, Madhya Pradesh, India
INTRODUCTION
Magnesium is:
third most abundant metal in the earths crust
an essential nutrient and primarily responsible for catalytic reaction of over 300 enzymes.
fourth most abundant mineral in the human body.
essential for plants in chlorophyll synthesis and photosynthesis.
Magnesium Deficiency:
The magnesium is found in many food ingredients but it is usually present in very low levels.
Thus, deficiency of magnesium is likely common among geriatric, obese, diabetics, and alcoholic
people.
Deficiency of the magnesium in human body, known as hypomagnesaemia.
Hypomagnesaemia causes many diseases such as osteoporosis, diabetes, and heart disease .
Currently, magnesium deficiency can be overcome by increase of magnesium concentration in
diet or through oral supplements.
Dissolution, absorption, bioavailability, and permeability plays a major role in oral supplement of
Magnesium.
STUDY DESIGN
The aim of present study was to evaluate the effect of Biofield Treatment on atomic
and physical properties of Magnesium Powder.
Biofield Treatment:
Human has ability to harness the energy from environment/ universe and can transmit into any
object (living or non-living) around the Globe. The object(s) always receive the energy and
responded into useful way that is called biofield energy and this process is termed as biofield
treatment.
Magnesium powder was divided into two parts denoted as control and treatment.
Treated group was in sealed pack and handed over to Mr. Trivedi for biofield treatment under
laboratory condition.
Control
Control
Mg
Magnesium
Treated
Biofield
Energy
Mg
Magnesium
Mr. Trivedi provided the biofield treatment through his energy transmission process to the treated
group without touching the sample.
EXPERIMENT
X-ray
diffraction
study
XRD analysis
of control and
treated
magnesium
powder was
carried out on
Phillips,
Holland PW
1710 X-ray
diffractometer
system, which
had a copper
anode with
nickel filter.
Surface Area
Analysis
Particle size
analysis
The surface
area was
measured by
the Surface
area analyzer,
Smart SORB 90
based on
Brunauer
EmmettTeller
(BET), which
had a
detection
range of 0.20
1000 m2/g.
Particle size of
control and
treated
magnesium
powder was
evaluated
using, laser
particle size
analyzer
SYMPATEC
HELOS-BF,
which had a
detection
range of 01875 m.
RESULTS
Unit cell
Lattice
volume
parameter
(10()
23
cm3)
Density
(g/cc)
Atomic
weight
(g/mol)
Nuclear
Change Crystallite
per unit
size
volume
(nm)
3
(C/cm )
Control, Day
3.2094
4.6525
1.7275
24.205
110892.80
87.16
0
Treated, Day
3.2120
4.6600
1.7248
24.244
110625.20
72.60
7
Treated, Day
3.2115
4.6586
1.7253
24.237
110675.07
72.60
41
Treated, Day
3.2109
4.6568
1.7260
24.228
110739.24
62.23
63
Control, Day
3.2094
4.6525
1.7275
24.205
110892.80
87.16
Table:
0 XRD results of control and treated magnesium samples are presented in the below Table.
The crystallite size was decreased from 87.16 (control) to 72.60, 72.60, and 62.23 nm
in treated magnesium sample on day 7, 41, and 63, respectively as compared to
control.
Crystallite size of treated magnesium powder was significantly reduced by 16.70,
16.70, and 28.60% on day 7, 41, and 63, respectively as compared to control.
Thus, it is hypothesized that biofield treated magnesium powder may exhibit the
higher dissolution rate as compared to control.
Group
Surface Area
(m2/g)
Control, Day 0
0.2975
Treated, Day 6
0.4061
Treated, Day 72
0.3294
Treated, Day 92
0.2000
Group
Control, Day 0
0.2975
Treated, Day 6
0.4061
Treated, Day 72
0.3294
Treated, Day 92
0.2000
Hence, it is assumed that biofield treated magnesium powder, having higher surface
area may exhibit higher rate of dissolution as compared to control.
This higher dissolution of a mineral in the human gastric fluid, make it easily
available for absorption in the body, which may results into higher bioavailability as
compared to control.
Groups
d10(m)
d50(m)
d99(m)
Control, Day 0
89.75
256.7
501.5
Treated, Day 10
79.79
260.7
502.3
Treated, Day 75
137.87
290.5
500.1
Treated, Day 80
83.69
261.5
498.4
Treated, Day 98
76.79
252.6
498.9
Table: d10, d50, and d99, size below which 10, 50, and 99% particles are
magnesium powder.
present, respectively.
D10
1.
It indicates that d10in treated sample was reduced by 11.09% on day 10 as compared to control, which might be responsible for
increase in surface area.
2.
Further, d10was increased by 53.61% as compared to control on day 75. It is possible that fresh surface generated through
fracturing, possibly welded with each other and increased particle size.
3.
Furthermore, d10was reduced by 6.75 and 14.44% on day 80 and 98 respectively as compared to control.
Groups
d10(m)
d50(m)
d99(m)
Control, Day 0
89.75
256.7
501.5
Treated, Day 10
79.79
260.7
502.3
Treated, Day 75
137.87
290.5
500.1
Treated, Day 80
83.69
261.5
498.4
Treated, Day 98
76.79
252.6
498.9
Table: d10, d50, and d99, size below which 10, 50, and 99% particles are
magnesium powder.
present, respectively.
D50
1.
In addition, average particle size, d50was changed from 256.7 m (control) to 260.7, 290.5, 261.5, and 252.6 m in treated
magnesium powder on day 10, 75, 80, and 98, respectively.
2.
It suggests that d50was increased by 0.16, 13.17, and 1.87% powder on day 10, 75, and 80 respectively, whereas it was slightly
decreased by 1.59% as compared to control on day 98.
Groups
d10(m)
d50(m)
d99(m)
Control, Day 0
89.75
256.7
501.5
Treated, Day 10
79.79
260.7
502.3
Treated, Day 75
137.87
290.5
500.1
Treated, Day 80
83.69
261.5
498.4
Treated, Day 98
76.79
252.6
498.9
Table: d10, d50, and d99, size below which 10, 50, and 99% particles are
magnesium powder.
present, respectively.
D99
1.
Larger particle size d99was reduced from 501.5 m (control) to 502.3, 500.1, 498.4, and 498.9 m in treated magnesium
powder on day 10, 75, 80, and 98, respectively
2.
Groups
d10(m)
d50(m)
d99(m)
Control, Day 0
89.75
256.7
501.5
Treated, Day 10
79.79
260.7
502.3
Treated, Day 75
137.87
290.5
500.1
Treated, Day 80
83.69
261.5
498.4
Treated, Day 98
76.79
252.6
498.9
Table: d10, d50, and d99, size below which 10, 50, and 99% particles are
magnesium powder.
present, respectively.
1. Thus, the particle size data suggest that medium (d50) and smaller (d10) size particles were more
affected through biofield treatment as compared to large (d99) particles.
2. Therefore, particle size and surface area result suggest that biofield treatment has altered the
physical properties of magnesium powder.
CONCLUSION
In Summary
XRD data revealed that biofield treatment has increased the unit cell volume and atomic weight up to
0.16% and reduced the nuclear charge per unit volume up to 0.24%, as compared to control.
The crystallite size of treated magnesium was significantly reduced up to 28.59% as compared to
control.
It is assumed that the internal strain induced by biofield treatment may fracture the crystallite and
reduced crystallite size.
Besides, the surface area of treated magnesium was increased up to 36.5% as compared to control.
It is assumed that higher surface area and lower crystallite size in treated magnesium might exhibits the
higher dissolution rate in human gastric fluid and may lead to increase the bioavailability of magnesium
ions in the body.
The biofield treatment has significantly altered the atomic and physical properties of magnesium
powder.
ACKNOWLEDGEMENT
& LINKS
THANK YOU
For your attention!